GT Biopharma, Inc. Quarterly Operating Lease, Liability in USD from Q1 2022 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Present value of lessee's discounted obligation for lease payments from operating lease.
Summary
GT Biopharma, Inc. quarterly Operating Lease, Liability history and growth rate from Q1 2022 to Q1 2024.
  • GT Biopharma, Inc. Operating Lease, Liability for the quarter ending March 31, 2024 was $30K, a 80.9% decline year-over-year.
Operating Lease, Liability, Quarterly (USD)
Operating Lease, Liability, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q1 2024 $30K -$127K -80.9% Mar 31, 2024 10-Q 2024-05-15
Q4 2023 $58M +$57.8M +33233% Dec 31, 2023 10-K 2024-03-26
Q3 2023 $97K -$217M Sep 30, 2023 10-Q 2023-11-01
Q2 2023 $156K -$246M Jun 30, 2023 10-Q 2023-08-07
Q1 2023 $157K -$277M Mar 31, 2023 10-Q 2023-05-15
Q4 2022 $174K Dec 31, 2022 10-K 2023-03-30
Q3 2022 $217M* Sep 30, 2022 10-Q 2022-10-31
Q2 2022 $246M* Jun 30, 2022 10-Q 2022-08-15
Q1 2022 $277M* Mar 31, 2022 10-Q 2022-05-16
* An asterisk sign (*) next to the value indicates that the value is likely invalid.